UCLA Medical Center, Santa Monica

UCLA Health

Santa Monica, CA

Sorting 2 by

Accepting patients

QUINTESSENTIAL-2

A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
Learn more
  • CAR T Cell
  • GPRC5D
  • Randomization
  • Phase 3

Not yet accepting

Cemsidomide in Combination With Elranatamab

A Phase 1B, Open-label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Learn more
  • IKZF1/3
  • Phase 1